thumbnail image

UE LifeSciences

  • Innovations 
    • iBreastExam
    • cervAIcal
  • About Us 
    • Journey
    • Team
  • Newsletter 
    • January 2023
    • 2022 Recap
  • Contact Us
  • …  
    • Innovations 
      • iBreastExam
      • cervAIcal
    • About Us 
      • Journey
      • Team
    • Newsletter 
      • January 2023
      • 2022 Recap
    • Contact Us
Stay Abreast

UE LifeSciences

  • Innovations 
    • iBreastExam
    • cervAIcal
  • About Us 
    • Journey
    • Team
  • Newsletter 
    • January 2023
    • 2022 Recap
  • Contact Us
  • …  
    • Innovations 
      • iBreastExam
      • cervAIcal
    • About Us 
      • Journey
      • Team
    • Newsletter 
      • January 2023
      • 2022 Recap
    • Contact Us
Stay Abreast
  • Investor Portal is Now Closed

    Company Highlights

    • Growth-stage, innovation driven, impact oriented Women’s Health Company 
    • Painless, radiation-free solutions for breast & cervical cancer detection
    • US FDA cleared product has pre-screened 500,000 women in 10 countries
    • Global commercialization in collaboration with Pfizer, Siemens & others
    • High-margin recurring revenue model in multibillion-dollar global market
    • Awarded by The World Bank, IFC. Recognized by WHO & ACOG TV 
    • Featured in the New York Times, Forbes, BBC, Vogue, & TED Talks

    News! 

    Jan 18 >  Siemens Medical Distribution Agreement Announced
    Jan 5 > Global Women's HealthTech Award from The World Bank, IFC & CTA
    Dec 24 > "Full Body Goosebump!" - Motley Fool Podcast discusses UELS
    Nov 17 > UE LifeSciences wins the Innovation Challenge! 
    Nov 9 > $1,000,000 in investment commitments received in the first week.
    Nov 2 > unanimous commitment of investment from the Circle of Money panel at the Unicorn Hunters Read Press Release

     

  • Too Many Women Are Dying

    From Preventable Cancers

    Problem Statement

    Breast and cervical cancers are the most common and lethal cancers in the world for women. Globally, 90% of women have limited access to early detection— most get diagnosed at stage 3 and 4, with poor prognosis.

  • Early Detection can 

    save Millions of Lives

    Solution

    We are a women’s health company laser-focused on preventive oncology. We design, develop and commercialize hand-held, non-invasive, effective and easy to use medical devices and app-based platforms - built for mass adoption in B2B settings and soon for the consumer’s self-use, at home (B2C).

  • We’re commercializing and developing new breakthrough sensor technologies that can detect tumors and lesions instantly at the point of care, without requiring expert interpretation, virtually in any setting and without any pain or radiation.

  • Products Built for Scale

    breakthrough products designed for massive scale across B2B & B2C markets.

    iBreastExam (B2B)

    Award-winning, patent-pending, radiation-free, ultra-portable wireless device, usable by lay health-workers to identify and document small, non-palpable lumps, quickly and easily, at the point-of-care.

    FDA cleared. In commercialization.

    cervAIcal (B2B)

    AI enabled mobile colposcope
    for cervical cancer screening. CervAIcal is a high-quality, wireless universal cervical examination assistant that goes where the patients are. Ongoing Pilots.

    Selfi (B2C)

    World's first, at home

    breast health monitoring
    device / app / platform
    built with iBreastExam technology

    Commercial launch expected in 2022

  • Validations, Approvals
    Partnerships, Awards & Press

    Traction

    As we continue developing and commercializing our proprietary products, UE LifeSciences has secured major research milestones, commercial partnerships, multiple international awards, and press features.

  • 450,000 women

    examined and help diagnose 200+ cancer cases

    Pfizer Collaboration

    Global Agreement in April 21 to market & scale iBreastExam

    >$3M in revenues

    since 2018; from 750 devices and 1.5M scans

    10 countries entered

    with regulatory approvals & distribution channels

  • UE Lifesciences on The New York Times

    Article

    TED Talks Shah Rukh Khan about UE LifeSciences

    Video

    UE LifeSciences on BBC News

    Video

     

    YourStory UE LifeSciences

    Article

    UE LifeSciences Featured on Forbes

    Article

  • Validations & Publications by Global Experts & Clinical Advisors

     

    Our Clinical Advisory Team consists of globally recognized experts and key opinion leaders in breast cancer control and treatment. 7,500 women have been enrolled in multiple investigator-led clinical validations with publications in leading international, peer-reviewed journals:

    In conclusion, this study demonstrated excellent negative predictive value of iBE and agreement between iBE and CBE as triage tests for the detection of clinically relevant breast lesions.
    iBreastExam identified 15 women with a correlating BIRAD 4 score, of which 3 were confirmed as early-stage breast cancers (Stage IIA, IA and DCIS), none with palpable abnormality on clinical breast examination.
     
    97% of the participants reported the test as acceptable and recommendable to relatives and 98% expressed an interest to have iBreastExam made available at local Public Health Centers.
    This validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.
    Identified abnormalities in all 39 patients who presented with breast abnormalities and did not demonstrate any false negatives that would prevent the patients from additional evaluation, which makes it a good prescreening tool.
    iBreastExam demonstrated significantly (23%) higher sensitivity and moderately (9%) higher specificity to detect breast lesions as compared to CBE. Lower FP rates compared to CBE reduces the pool of women requiring further diagnostic follow-up. iBreastExam requires minimal training and provides objective breast examination with digital documentation
  • Awards & Recognitions

    2021 Thought Leader

    ACOG TV, ACOG 2021 (American College of Obstetricians and Gynecologists Annual Meeting)

    Innovative Health Technology

    World Health Organization, Compendium of innovative health technologies for low-resource settings

    $1.7M in Global Grant Awards

    Innovation, Global Health & Oncology

    • Pennsylvania Department of Health, CURE Grant Award ($878,000)
    • Global Health Innovation Grant, Pfizer Foundation ($200,000)
    • Grants 4 Impact, Bayer Cares Foundation ($175,000)
    • StartHealth, Unitus Seed Fund ($80,000)
    • Digital Health Accelerator, University City Science Center ($50,000)
    • Helsinn – Lyfebulb Oncology Innovation Award ($25,000)
    • Aspirin Innovation Award, Bayer Cares Foundation ($20,000)
    • HITLabs World Cup Award NY
    • Accenture Healthcare Innovation Challenge Award
    • Inclusive Innovation Award, Anjani Mashelkar Foundation
    • Arab Health Innov8 Award, Dubai
    • Lexus Design Award, India
    • IBM Smart Camp for HealthTech India
    • Marcum Innovator of the Year Award
    • PACT Enterprise Awards LifeSciences Startup Company

    Interested to invest? Let's go!

    Start Your Investment Here
  • Over 100 years of team experience

    Renowned Investors, KOL Advisors

    People & Plans

    Our team collectively brings together over 100 years of med-tech commercialization experience. We are backed by reputed investors and advisors.

  • Leadership Team

    USA | India | Malaysia

    Backers & Partners

    Enabling our Vision

    Mihir Shah

    Co-Founder & CEO

    Matt Campisi

    Co-Founder & CTO

    Our Journey

    Dreams in Action

  • We're at the Intersection of 

    Multiple Rapidly Growing Markets

    Market

    Women’s Health (or FemTech) set to be a $50B global market by Yr 2025.
    Tele-Health is $22 billion US market in 2020, growing at a CAGR of 28%.
    Increasing adoption of wearables, IoT and other med-devices at home.

  • Investor Portal is Now Closed

Home

Journey

Team

Newsletter

+1.267.225.0453

info@UELifeSciences.com

iBreastExam

cervAIcal

UE LifeSciences Inc. Copyright © 2021 | Terms & Conditions

    Invest
    News
    Call
    Email
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More